Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 12/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | DHFR | P00374 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.40 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4421811 | 0.82 | HRH3 (0.43) | HRH3FFAR1 | |
| SCHEMBL2913656 | 0.81 | MEN1 (0.50) | MEN1NPC1RAB9AKMT2ADHFR | |
| SCHEMBL986213 | 0.80 | HRH3 (0.46) | HRH3 | |
| SCHEMBL3057524 | 0.80 | MEN1 (0.54) | MEN1NPC1RAB9AKMT2ADHFR | |
| SCHEMBL4766452 | 0.79 | MEN1 (0.57) | MEN1NPC1RAB9AKMT2ADHFR | |
| SCHEMBL12367574 | 0.78 | HRH3 (0.51) | HRH3PRMT5WDR77 | |
| SCHEMBL2907874 | 0.76 | KMT2A (0.54) | MEN1NPC1RAB9AKMT2ADHFR | |
| SCHEMBL12367573 | 0.75 | HRH3 (0.55) | HRH3 | |
| SCHEMBL6672252 | 0.74 | HRH3 (0.73) | HRH3 | |
| SCHEMBL2907270 | 0.74 | KMT2A (0.57) | MEN1NPC1RAB9AKMT2ADHFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1756104-B1 | TETRAHYDRONAPHTHYRIDINE DERIVATIVES USEFUL AS HISTAMINE H3 RECEPTOR LIGANDS | PFIZER LTD (GB) | 2010-12-15 | — | — | EP | disclosed |
| US-20090258861-A1 | Tetrahydronaphthyridine Derivatives | LUNN GRAHAM | 2009-10-15 | — | — | US | disclosed |
| US-7557121-B2 | Tetrahydronaphthyridine derivatives | PFIZER INC (US) | 2009-07-07 | — | — | US | disclosed |
| EP-1945639-A1 | TETRAHYDRONAPHTHYRIDINE DERIVATIVE | Pfizer Limited (GB) | 2008-07-23 | — | — | EP | disclosed |
| US-20070179175-A1 | Tetrahydronaphthyridine Derivative | PFIZER LIMITED (GB) | 2007-08-02 | — | — | US | disclosed |
| US-20070179175-A1 | Tetrahydronaphthyridine Derivative | PFIZER LIMITED (GB) | 2007-08-02 | — | — | US | disclosed |
| US-20070179175-A1 | Tetrahydronaphthyridine Derivative | PFIZER LIMITED (GB) | 2007-08-02 | — | — | US | disclosed |
| WO-2007052124-A1 | TETRAHYDRONAPHTHYRIDINE DERIVATIVE | PFIZER LIMITED (GB) | 2007-05-10 | — | — | WO | disclosed |
| WO-2007052124-A1 | TETRAHYDRONAPHTHYRIDINE DERIVATIVE | PFIZER LIMITED (GB) | 2007-05-10 | — | — | WO | disclosed |
| EP-1756104-A1 | TETRAHYDRONAPHTHYRIDINE DERIVATIVES USEFUL AS HISTAMINE H3 RECEPTOR LIGANDS | Pfizer Limited (GB) | 2007-02-28 | — | — | EP | disclosed |
| WO-2005111036-A1 | TETRAHYDRONAPHTHYRIDINE DERIVATIVES USEFUL AS HISTAMINE H3 RECEPTOR LIGANDS | PFIZER LIMITED (GB) | 2005-11-24 | — | — | WO | disclosed |
| US-20050256135-A1 | Tetrahydronaphthyridine derivatives | LUNN GRAHAM | 2005-11-17 | — | — | US | disclosed |
| EP-1595881-A1 | Tetrahydronaphthyridine derivates useful as histamine H3 receptor ligands | Pfizer Limited (GB) | 2005-11-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256135-A1 | Tetrahydronaphthyridine derivatives | HRH4, HRH3, HRH1 | HRH3 2/4885MEN1 2391/4885NPC1 1444/4885 |
| US-20090258861-A1 | Tetrahydronaphthyridine Derivatives | HRH4, HRH3, HRH1 | HRH3 2/4885MEN1 2391/4885NPC1 1444/4885 |
| US-20070179175-A1 | Tetrahydronaphthyridine Derivative | HRH4, HRH3, HRH1 | HRH3 2/4885MEN1 3382/4885NPC1 719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.